Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector126710.17816/ACEN.1267ReviewsОбзорыReview ArticlePharmacological functional MRI technology: potential for use in neurologyТехнология фармакологической функциональной МРТ: потенциал использования в неврологииhttps://orcid.org/0000-0003-0522-767XRaskurazhevAnton A.РаскуражевАнтон Алексеевич
Russian Federation

Cand. Sci. (Med.), neurologist, senior researcher, 1st Neurological department, Head, Laboratory of neuropharmacological functional MRI, Institute of Clinical and Preventive Neurology

канд. мед. наук, врач-невролог, с. н. с. 1-го неврологического отделения, рук. лаб. нейрофармакологической функциональной МРТ Института клинической и профилактической неврологии

raskurazhev@neurology.ruhttps://orcid.org/0000-0002-5883-8119TanashyanMarine М.ТанашянМаринэ Мовсесовна
Russian Federation

Dr. Sci. (Med.), Professor, Corr. Member of the Russian Academy of Sciences, Deputy Director for research, Head, 1st Neurological department, Institute of Clinical and Preventive Neurology

д-р мед. наук, профессор, член-корреспондент РАН, заместитель директора по научной работе, руководитель 1-го неврологического отделения Института клинической и профилактической неврологии

raskurazhev@neurology.ruhttps://orcid.org/0000-0002-9093-344XMorozovaSofya N.МорозоваСофья Николаевна
Russian Federation

Cand. Sci. (Med.), researcher, Radiology department, Institute of Clinical and Preventive Neurology

канд. мед. наук, н. с. отдела лучевой диагностики Института клинической и профилактической неврологии

raskurazhev@neurology.ruhttps://orcid.org/0000-0002-4626-6520KuznetsovaPolina I.КузнецоваПолина Игоревна
Russian Federation

Cand. Sci. (Med.), neurologist, researcher, 1st Neurological department, Institute of Clinical and Preventive Neurology

канд. мед. наук, врач-невролог, н. с. 1-го неврологического отделения Института клинической и профилактической неврологии

raskurazhev@neurology.ruhttps://orcid.org/0000-0002-9120-2550AnnushkinVladislav A.АннушкинВладислав Александрович
Russian Federation

Cand. Sci. (Med.), neurologist, 1st Neurological department, Institute of Clinical and Preventive Neurology

канд. мед. наук, врач-невролог 1-го неврологического отделения Института клинической и профилактической неврологии

raskurazhev@neurology.ruhttps://orcid.org/0000-0001-8960-721XMazurAndrey S.МазурАндрей Сергеевич
Russian Federation

postgraduate student, 1st Neurological department, Institute of Clinical and Preventive Neurology

аспирант 1-го неврологического отделения Института клинической и профилактической неврологии

raskurazhev@neurology.ruhttps://orcid.org/0000-0002-8652-2947PaninaAnastasya A.ПанинаАнастасия Андреевна
Russian Federation

postgraduate student, 1st Neurological department, Institute of Clinical and Preventive Neurology

аспирантка 1-го неврологического отделения Института клинической и профилактической неврологии

raskurazhev@neurology.ruhttps://orcid.org/0000-0002-2934-5462SpryshkovNikita E.СпрышковНикита Евгеньевич
Russian Federation

postgraduate student, 1st Neurological department, Institute of Clinical and Preventive Neurology

аспирант 1-го неврологического отделения Института клинической и профилактической неврологии

raskurazhev@neurology.ruhttps://orcid.org/0000-0002-6338-0392PiradovMikhail A.ПирадовМихаил Александрович
Russian Federation

Dr. Sci. (Med.), Professor, Full member of the Russian Academy of Sciences, Director

д-р мед. наук, профессор, академик РАН, директор

raskurazhev@neurology.ruResearch Center of NeurologyНаучный центр неврологии1503202519168761701202527012025Copyright ©; 2025, Raskurazhev A.A., Tanashyan M.М., Morozova S.N., Kuznetsova P.I., Annushkin V.A., Mazur A.S., Panina A.A., Spryshkov N.E., Piradov M.A.Copyright ©; 2025, Раскуражев А.А., Танашян М.М., Морозова С.Н., Кузнецова П.И., Аннушкин В.А., Мазур А.С., Панина А.А., Спрышков Н.Е., Пирадов М.А.2025Raskurazhev A.A., Tanashyan M.М., Morozova S.N., Kuznetsova P.I., Annushkin V.A., Mazur A.S., Panina A.A., Spryshkov N.E., Piradov M.A.Раскуражев А.А., Танашян М.М., Морозова С.Н., Кузнецова П.И., Аннушкин В.А., Мазур А.С., Панина А.А., Спрышков Н.Е., Пирадов М.А.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/1267

This review presents recent data on one of the most promising neuroimaging techniques, pharmacological functional magnetic resonance imaging (phFMRI). PhFMRI technologies are described as well as task-based approaches inducing neuronal activation in the areas of interest when evaluating the effects of neuroactive agents. We reviewed the potential use of phFMRI in various neurological disorders such as cerebrovascular disease and epilepsy, as well as in the management of metabolic disorders, cognitive impairment, pain syndrome, etc. Limitations of phFMRI and possible ways to address them in designing and conducting studies are presented. The potential uses of phFMRI for the objective assessment of the targeted effects of pharmacological agents are suggested.

В обзоре представлены современные данные об одной из перспективных нейровизуализационных методик — фармакологической функциональной магнитно-резонансной томографии (фарм-фМРТ). Описаны технологии проведения фарм-фМРТ, варианты применения парадигмы в качестве триггера нейрональной активации зон интереса при изучении эффектов нейроактивных препаратов. Рассмотрены потенциальные возможности применения фарм-фМРТ при различных неврологических состояниях, таких как цереброваскулярные заболевания, эпилепсия, а также в отношении коррекции метаболических расстройств, когнитивных нарушений, болевого синдрома и др. Представлены ограничения применения фарм-фМРТ, возможные пути их преодоления при планировании и проведении исследований. Предложены перспективы применения фарм-фМРТ, которые позволят дать объективную оценку таргетного воздействия фармакологических агентов.

pharmacological magnetic resonance imagingfunctional magnetic resonance imagingtargeted effectsparadigmpersonalized medicineфармакологическая магнитно-резонансная томографияфункциональная магнитно-резонансная томографиятаргетное воздействиепарадигмаперсонифицированная медицинаMinistry of Science and Higher Education of the Russian FederationМинистерство науки и высшего образования Российской Федерации1023102700108-5Dawson GR, Craig KJ, Dourish CT. Validation of experimental medicine methods in psychiatry: the P1vital approach and experience. Biochem Pharmacol. 2011;81(12):1435–1441. DOI: 10.1016/j.bcp.2011.03.013Conn PJ, Roth BL. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology. 2008;33(9):2048–2060. DOI: 10.1038/sj.npp.1301638Bandettini PA, Wong EC, Hinks RS, et al. Time course EPI of human brain function during task activation. Magn. Reson. Med. 1992;25(2):390–397. DOI: 10.1002/mrm.1910250220Ogawa S, Tank DW, Menon R, et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci USA. 1992;89(13):5951–5955. DOI: 10.1073/pnas.89.13.5951Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A. 1992;89(12):5675–5679. DOI: 10.1073/pnas.89.12.5675Jenkins BG. Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain. Neuroimage. 2012;62(2):1072–1085. DOI: 10.1016/j.neuroimage.2012.03.075Chen YC, Galpern WR, Brownell AL, et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med. 1997;38(3):389–398. DOI: 10.1002/mrm.1910380306Silva AC, Zhang W, Williams DS, Koretsky AP. Multi-slice MRI of rat brain perfusion during amphetamine stimulation using arterial spin labeling. Magn Reson Med. 1995;33(2):209–214. DOI: 10.1002/mrm.1910330210Cuenod CA, Chang MCJ, Arai T, et al. Local brain response to cholinergic receptor stimulation detected by MRI. Proc Int Soc Magn Reson Med. 1993:S3;1387.Wandschneider B, Koepp MJ. Pharmaco fMRI: determining the functional anatomy of the effects of medication. Neuroimage Clin. 2016;12:691–697. DOI: 10.1016/j.nicl.2016.10.002Upadhyay J, Anderson J, Baumgartner R, et al. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. Neuroimage. 2012;59(4):3762–3773. DOI: 10.1016/j.neuroimage.2011.11.034Fanny M, Manuel T, Daniel HW, et al. Pharmacological manipulation of neurotransmitter activity induces disparate effects on cerebral blood flow and resting-state fluctuations. Imaging Neuroscience. 2024;2:1–18. DOI: 10.1162/imag _a_00370Jenkins BG. Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain. Neuroimage. 2012;62(2):1072–1085. DOI: 10.1016/j.neuroimage.2012.03.075Carmichael O, Schwarz AJ, Chatham CH, et al. The role of fMRI in drug development. Drug Discov Today. 2018;23(2):333–348. DOI: 10.1016/j.drudis.2017.11.012Delaveau P, Jabourian M, Lemogne C, et al. Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. J Affect Disord. 2011;130(1-2):66–74. DOI: 10.1016/j.jad.2010.09.032van Wingen GA, Tendolkar I, Urner M, et al. Short-term antidepressant administration reduces default mode and task-positive network connectivity in healthy individuals during rest. Neuroimage. 2014;88:47–53. DOI: 10.1016/j.neuroimage.2013.11.022Harris RE, Napadow V, Huggins JP, et al. Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. Anesthesiology. 2013;119(6):1453–1464. DOI: 10.1097/ALN.0000000000000017Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34(4):537–541. DOI: 10.1002/mrm.1910340409Gaebler AJ, Fakour N, Stöhr F, et al. Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRI. Transl. Psychiatry. 2023;13(1):59. DOI: 10.1038/s41398-023-02344-2Berginström N, Nordström P, Ekman U, et al. Pharmaco-fMRI in patients with traumatic brain injury: a randomized controlled trial with the monoaminergic stabilizer (-)-OSU6162. J Head Trauma Rehabil. 2019;34(3):189–198. DOI: 10.1097/HTR.0000000000000440Танашян М.М., Лагода О.В., Федин П.А. и др. Современные подходы к лечению больных с хроническими сосудистыми заболеваниями головного мозга. Нервные болезни. 2010;(4):19–22. Tanashyan MM, Lagoda OV, Fedin PA, et al. Modern approaches to the treatment of patients with chronic vascular diseases of the brain. Nervnyye bolezni. 2010;(4):19–22.Танашян М.М., Бархатов Д.Ю., Глотова Н.А. и др. Эффективность нейропротекции у больных с хроническими цереброваскулярными заболеваниями. Вестник Российской военно-медицинской академии. 2011;3(35):181–187. Tanashyan MM, Barkhatov DYu, Glotova NA, et al. The effectiveness of neuroprotection in patients with chronic cerebrovascular diseases. Bulletin of the Russian Military Medical Academy, 2011;3(35):181–187.Танашян М.М., Коновалов Р.Н., Лагода О.В. Новые подходы к коррекции когнитивных нарушений при цереброваскулярных заболеваниях. Анналы клинической и экспериментальной неврологии. 2018;12(3):30–39. DOI: 10.25692/ACEN.2018.3.4 Tanashyan MM, Konovalov RN, Lagoda OV. New approaches to correction of cognitive impairments in cerebrovascular diseases. Annals of clinical and experimental Neurology. 2018;12(3):30–39. DOI: 10.25692/ACEN.2018.3.4Tanashyan M, Morozova S, Raskurazhev A, Kuznetsova P. A prospective randomized, double-blind placebo-controlled study to evaluate the effectiveness of neuroprotective therapy using functional brain MRI in patients with post-covid chronic fatigue syndrome. Biomed Pharmacother. 2023;168:115723. DOI: 10.1016/j.biopha.2023.115723Becerra L, Harter K, Gonzalez RG, Borsook D. Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg. 2006;103(1):208–216. DOI: 10.1213/01.ane.0000221457.71536.e0Gear R, Becerra L, Upadhyay J, et al. Pain facilitation brain regions activated by nalbuphine are revealed by pharmacological fMRI. PLoS One. 2013;8(1):e50169. DOI: 10.1371/journal.pone.0050169Edes AE, McKie S, Szabo E, et al. Increased activation of the pregenual anterior cingulate cortex to citalopram challenge in migraine: an fMRI study. BMC Neurol. 2019;19(1):237. DOI: 10.1186/s12883-019-1478-0Vollmar C, O’Muircheartaigh J, Symms MR, et al. Altered microstructural connectivity in juvenile myoclonic epilepsy: the missing link. Neurology. 2012;78(20):1555–1559. DOI: 10.1212/WNL.0b013e3182563b44Wandschneider B, Stretton J, Sidhu M, et al. Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. Neurology. 2014;83(17):1508–1512. DOI: 10.1212/WNL.0000000000000910De Ciantis A, Muti M, Piccolini C, et al. A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate. Neurol Sci. 2008;29(Suppl 1):S141–143. DOI: 10.1007/s10072-008-0906-5Jansen JF, Aldenkamp AP, Marian Majoie HJ, et al. Functional MRI reveals declined prefrontal cortex activation in patients with epilepsy on topiramate therapy. Epilepsy Behav. 2006;9(1):181–185. DOI: 10.1016/j.yebeh.2006.05.004Szaflarski JP, Allendorfer JB. Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy. Epilepsy Behav. 2012;24(1):74–80. DOI: 10.1016/j.yebeh.2012.02.022Tang Y, Xia W, Yu X, et al. Altered cerebral activity associated with topiramate and its withdrawal in patients with epilepsy with language impairment: an fMRI study using the verb generation task. Epilepsy Behav. 2016;59:98–104. DOI: 10.1016/j.yebeh.2016.03.013Yasuda CL, Centeno M, Vollmar C, et al. The effect of topiramate on cognitive fMRI. Epilepsy Res. 2013;105(1-2):250-255. DOI: 10.1016/j.eplepsyres.2012.12.007Танашян М.М., Антонова К.В. Цереброметаболическое здоровье. В кн.: Управление метаболическим здоровьем. М.; 2025;II:117–148. Tanashyan MM, Antonova KV. Cerebrometabolic health. In: Management of metabolic health. Moscow; 2025;II:119–148. (In Russ.)Кремнева Е.И., Суслин А.С., Говорин A.Н. и др. фМРТ-картирование алиментарных функциональных зон головного мозга. Анналы клинической и экспериментальной неврологии. 2015;9(1):32–36. DOI: 10.17816/psaic156 Kremneva EI, Suslin AS, Govorin AN, et al. Mapping of the brain regions responsible for eating behavior regulation with functional MRI. Annals of clinical and experimental neurology. 2015;9(1):32–36. DOI: 10.17816/psaic156Кузнецова П.И., Романцова Т.И., Логвинова О.В. и др. Функциональная МР-томография головного мозга на фоне медикаментозной коррекции ожирения. Ожирение и метаболизм. 2022;19(1):74–82. DOI:10.14341/omet12810 Kuznetsova PI, Romantsova TI, Logvinova OV, et al. Functional brain MRI in the setting of drug correction of obesity. Obesity and metabolism. 2022;19(1):74–82. DOI:10.14341/omet12810Farr OM, Tsoukas MA, Triantafyllou G, et al. Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study. Metabolism. 2016;65(7):945–953. DOI: 10.1016/j.metabol.2016.03.009Cheng H, Zhang Z, Zhang B, et al. enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: a 16-week randomized parallel comparative study. Diabetes Care. 2022;45(5):1201–1210. DOI: 10.2337/dc21-2064Goekoop R, Scheltens P, Barkhof F, et al. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation — a pharmacological fMRI study. Brain. 2006;129 (Pt 1):141–157. DOI: 10.1093/brain/awh671Bourke JH, Wall MB. phMRI: methodological considerations for mitigating potential confounding factors. Front Neurosci. 2015;9:167. DOI: 10.3389/fnins.2015.00167Glover GH, Li TQ, Ress D. Image-based method for retrospective correction of physiological motion effects in fMRI: RETROICOR. Magn Reson Med. 2000;44(1):162–167. DOI: 10.1002/1522-2594(200007)44:1<162::aid-mrm23>3.0.co;2-eMurphy SE, Mackay CE. Using MRI to measure drug action: caveats and new directions. J Psychopharmacol. 2011;25(9):1168–1174. DOI: 10.1177/0269881110372547Pattinson KT, Rogers R, Mayhew SD, et al. Pharmacological FMRI: measuring opioid effects on the BOLD response to hypercapnia. J Cereb. Blood Flow Metab. 2007;27(2):414–423. DOI: 10.1038/sj.jcbfm.9600347Deakin JF, Lees J, McKie S, et al. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65(2):154–164. DOI: 10.1001/archgenpsychiatry.2007.37Anderson IM, Clark L, Elliott R, et al. 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport. 2002;13(12):1547–1551. DOI: 10.1097/00001756-200208270-00012Cole DM, Smith SM, Beckmann CF. Advances and pitfalls in the analysis and interpretation of resting-state FMRI data. Front Syst Neurosci. 2010;4:8. DOI: 10.3389/fnsys.2010.00008